Could an Immune-Boosting drug ease autism symptoms?
NCT ID NCT07589842
First seen May 15, 2026 · Last updated Jun 23, 2026 · Updated 9 times
Summary
This phase 2 trial tests a low-dose immune drug called interleukin-2 (ILT-101) in 22 children aged 6 to 8 with moderate to severe autism whose mothers had an autoimmune condition during pregnancy. The goal is to see if the drug can increase helpful immune cells (Tregs) and improve social and behavioral symptoms. The study compares the drug to a placebo over 6 months of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTISM SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Robert Debré Hospital
Paris, 75019, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ILT-101 (low-dose interleukin-2)
What this could lead to
If it works, this could point toward a new treatment that improves social and behavioral symptoms in some children with autism.
What could go wrong
This is a very small, early-phase trial with only 22 children. It may not show clear benefits, and the treatment could cause side effects like injection reactions or immune changes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.